IL17A and psoriasis: We can safely postulate that the ScF relieves the severity of psoriasis by the reduction in epidermal cell overgrowth with anti-proliferative effect through the mTOR pathway through: (1) upregulation of anti-proliferative protein (decorin), (2) downregulation of antimicrobial peptide (β-defensin), apoptotic proteins (caspase-3 and -9), chemokine (CCL-20), proinflammatory cytokines (TNF-α, IL-1β, and IL-17), inflammatory modulator (S100a14, S100A8, ANXA1, Lyz1, and BSPB1), proliferative related proteins (TGF-β, Wnt, mTOR, and TEP1), and keratinized proteins (KRT14 and KRT75).